More than 30 studies are under way in France -- of a world total of 860 -- in search of drugs to treat the COVID-19 disease sweeping the world, infectologist Florence Ader said Sunday.
The research is "extremely active" in France involving some 1,600 patients, Ader told a news conference.
Ader heads up a study dubbed Discovery in collaboration with several other European countries, with researchers conducting clinical trials of four potential treatments including the controversial hydroxychloroquine.
Of some 3,200 patients in Europe, at least 800 are in France. All are in hospital and severely ill with COVID-19.
Around the world some 150 projects seek to develop a vaccine against the novel coronavirus. France's prestigious Institut Pasteur will carry out trials on humans by this summer, Ader said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app